Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

Official Title

Moderate Hypofractionated Boost to the Prostate With Pelvic RT in High Risk Prostate Cancer

Summary:

This is a single-arm phase II prospective trials that is recruiting 100 participants. The study population that is being investigated are patients with localized high-risk or node-positive prostate cancer. Participants will receive external beam radiation therapy as a moderately hypofractionated boost to the prostate with pelvic radiation therapy. Androgen deprivation therapy will be prescribed at the discretion of the treating physician as per standard of care.

Trial Description

Primary Outcome:

  • Acute Grade >2 Gastrointestinal Toxicity
Secondary Outcome:
  • Patient-reported quality-of-life assessed by EPIC-26
  • Measure the severity of lower urinary tract symptoms during the study
  • Graded criteria based on CTCAE version 5.0 for acute genitourinary toxicity and late genitourinary and gastrointestinal toxicity
  • Measure of oncologic outcomes
  • Measure of oncologic outcomes
  • Measure of onocologic outcomes
  • Prostate cancer specific survival based on death from prostate cancer
  • Overall survival

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society